CTRP long DEC 70 CALL and 60 PUT 2.90
earning
NO one can control future but you can manage present with using Stop loss always use them, i learnt by losing 150K in 2001.
BPAX expects to issue a safety update on LibiGel by the end of October.
Wave has been developing a service which combines hardware security and open identities for secure, single sign-on for accessing Web services. It utilizes OpenID and SAML, open standards that allow the use of an existing identity to sign into multiple websites without creating new passwords. With OpenID, a visited website (relying party) communicates with an identity provider and that provider then confirms the visitor's identity to the website. To date many sites including Google, FaceBook and SalesForce participate in OpenID as an identity provider, relying party or both.
DARA BioSciences Inc. ("DARA") is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis
http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20091005006488&newsLang=en
http://www.reuters.com/article/pressRelease/idUS108873+07-Oct-2009+PRN20091007
Fampridine-SR is being developed and commercialized by Acorda Therapeutics in the United States. A New Drug Application (NDA) for Fampridine-SR has been filed and assigned priority review by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009; the PDUFA date is the target date for FDA to complete its review of Fampridine-SR. In markets outside of the United States, Fampridine-SR will be developed and commercialized by Biogen Idec under a license from Acorda Therapeutics. Biogen Idec expects to file for approval by the European Medicines Agency (EMEA) in early 2010
http://www.earthtimes.org/articles/show/ap-pharma-receives-notice-related,966419.shtml
http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=104&STORY=/www/story/09-17-2009/0005096255&EDATE=
link
http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=DARA.O
Our fourth generation terahertz product, which we call the T-Ray 4000, is an instrument that can be used in the non-destructive testing and process control markets to provide real-time, two-dimensional measurements and 3-D imaging sub-surface. It also can yield some spectroscopic information or chemical composition of materials hidden beneath the surface. The T-Ray 4000 has already been adopted by NASA to inspect the sprayed-on foam insulation on the fuel tank used by the space shuttle and the tile on the space shuttle itself. It's now being investigated by Northrop and Lockheed for non-destructive testing applications on the new F-35 Joint Strike Fighter Program to measure the stealth material thickness. It is an emerging technology and, as such, we are transferring our terahertz system from the application development laboratory to the factory floor. We believe that the market opportunity for this technology will be over $200 million annually by 2017.
no position yet. but i 'll buy tomorrow a .90-.95c
CIBT Education Group Inc. formerly Capital Alliance Group Inc., is an educational, investment and marketing organization headquartered in Vancouver, B.C., Canada. The Company’s business operations include education and media communications. The Company has three principal business segments: CIBT School of Business & Technology Corp. (CIBT), Sprott-Shaw Degree College Corp. (SSDC) and IRIX Design Group Inc. (IRIX). The Company’s education business is conducted through CIBT and its subsidiaries in China. CIBT’s educational operations are based in China. The Company operates its media communications business through IRIX and its subsidiaries. IRIX is based in Canada with representatives in Hong Kong and the United States
Motorola to Unveil Android Handset on Sept. 10
Gonna follow JOHN PAulson
wpwowowowowoowow
TRUE ECOMMERCE BUSINESS recession proof http://www.iemployee.com/human-resources/online-benefits/
posted here at .30c packetvideo is hot future
Our backlog was approximately $251,963,000 at December 31, 2008. Approximately $90
500 dollar to 9500 I think JIMCRAMER needs to hire me(lol) kidding
these may gain 400-500% or lose 100%
straddle breakeven 142 or 117
up 1600% this year . it needs a pull back after earnings i guess
http://finance.yahoo.com/q/os?s=GOOG&m=2009-07-17
http://www.pharmalive.com/news/index.cfm?articleid=633233&search=1
The value proposition for video webcasting (Internet broadcasting) is a simple one: communicate a lot of information to many geographically dispersed individuals
simultaneously in the most cost-effective, captivating manner possible. Video webcasts are widely used around the world today for corporate communications, training, earnings announcements and live events. Though cost effective in terms of what they enable us to accomplish, they can be cost prohibitive for most organizations.
i sold too soon though
MSFT and YHOO their customers on affiliate program partner i guess.
and i guess FUTURE relies on it WAVE is very risky but huge reward if i am right max. loss .30 cents i bought few thousands for long term
10% gain only but it's free not a monthly premium like others
http://vfcsstockhouse.blogspot.com/2009/05/calling-on-citi-citi-calls-still.html
http://www.tmworld.com/article/CA6654765.html?industryid=47189
Hypercom Corporation’s HyperSafe Secure encrypts cardholder data during transaction processing so that sensitive information is never exposed. The solution specifically combats escalating criminal efforts to steal unencrypted cardholder data through breaches of merchant networks, applications and servers that store and transmit sensitive cardholder data. Hypercom will demonstrate its HyperSafe Secure solution at the Electronic Transaction Association’s annual meeting and exposition April 21-23 in Las Vegas.
http://seekingalpha.com/article/126894-elixir-gaming-technologies-inc-q4-2008-earnings-call-transcript?source=yahoo&page=3
from april 23rd post http://finance.yahoo.com/q?s=QTVEU.X
earnings in 2 days let's see 100% loss or MUCHOCOOOO gain
high risk may lose all if they miss i have only 10
http://www.glgroup.com/News/TZOO-launches-a-strong-product-offering---may-be-the-key-in-a-reversal-of-fortune-33304.html
no idea why but i think they may survive
i saw huge PUT vol.
| 03/25/2009 -- 04/18/2009 | ||||
| Created: 4/18/ | ||||
| Entire Period | ||||
| Short Term Gain | 5,574.25 | Long Term Gain | 0.00 | |
| Short Term Loss | 0.00 | Long Term Loss | 0.00 | |
| Short Term Net | 5,574.25 | Long Term Net | 0.00 | |
| Short Term Sales | 9,907.22 | Long Term Sales | 0.00 | |
| Short Term Cost | 4,332.97 | Long Term Cost | 0.00 | |
| Close Date | Rec type | Open Date | Security | Shares Sold | Sales | Cost | ST Gain/Loss | LT Gain/Loss |
| 04/09/2009 | 04/03/2009 | BAC CALL APR 8 (BYODH) | 1,300 | 931.42 | 563.55 | 367.87 | ||
| 04/13/2009 | 04/09/2009 | BAC CALL APR 10 (BYODJ) | 1,000 | 906.47 | 303.17 | 603.30 | ||
| 04/13/2009 | 04/09/2009 | BAC CALL MAY 14 (BYOEN) | 1,000 | 556.48 | 173.50 | 382.98 | ||
| 04/02/2009 | 03/30/2009 | C CALL APR 3 (CDV) | 1,600 | 362.39 | 271.40 | 90.99 | ||
| 04/13/2009 | 04/09/2009 | C CALL APR 3 (CDV) | 2,000 | 1,012.97 | 467.00 | 545.97 | ||
| 04/14/2009 | 04/13/2009 | C CALL APR 4 (CDW) | 6,000 | 3,038.92 | 1,161.00 | 1,877.92 | ||
| 04/14/2009 | 04/13/2009 | C CALL APR 4 (CDW) | 6,000 | 2,558.93 | 1,281.00 | 1,277.93 | ||
| 04/03/2009 | 04/02/2009 | RIMM CALL APR 55 (RFYDK) | 100 | 539.64 | 112.35 | 427.29 | ||
| Total: | 9,907.22 | 4,332.97 | 5,574.25 | |||||
earnings may 6 . last 2 news releases very positive, it was 4 bucks few months ago. bad earnings came and it was hammered. i see now opposite way.
http://www.newdragonasia.com/corp_profile.html
could be HUGE %%% gainer ot 100% loser HIGH risk GAMBLE money i have few thousands in IRA
high risk play i bought HOping for it to breakout for 100%+ gain
CARBON bill in congress
When we use a resource such as solar power to generate hydrogen as a fuel for fuel cell appliances and vehicles we have a truly renewable, non-polluting energy system," said Pierre Rivard, President and CEO of Hydrogenics. "This also emphasizes our commitment to developing the hydrogen solutions that are required by emerging markets, especially at this early demonstration stage. Being able to provide hydrogen generation devices, as well as fuel cell power products, differentiates Hydrogenics within the industry."
http://www.cardplayer.com/poker-news/article/6375/pro-poker-legislation-will-be-introduced-in-coming-weeks
Two Funds bought 1 million http://www.mffais.com/bcon.html
has cash until midle of 2010
nasdaq hearing march 12
it has 98 million cash = 69c per share cash and hedge fund may wake up
The Company is also currently conducting two additional randomized placebo controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial will include our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial is actively enrolling approximately 150 patients. The Company expects topline results from the first three months of treatment in early 2009. The second trial is a four arm comparator trial of two doses of elagolix, placebo or Leuprolide Depot. This trial is being conducted in Central and Eastern Europe. Topline data from this 3-month double-blind trial of approximately 180 patients should be available in the first half of 2009.
Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.
Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS
The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the GSK collaboration. The first lead compound (876008) is in a Phase II "proof of concept" trial to evaluate its safety and efficacy in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial. Standard assessments of safety, tolerability and pharmacokinetics will be conducted. The clinical endpoints reflect change in symptom frequency and severity via validated scales for IBS and the data should be available in the second half of 2008.
if not it may see Single digit but i think Icahn is praying 24 hrs a day for MSFT rescue
i hope to get at least 50-100% gain on it
more JUWI solar news
deadline jan 30 buyout upto 51% of shares @ .15 cents WOWOWOW
Due to the inherent intermittent nature of alternative energy sources such as wind and solar, companies that focus on such green technologies have long sought a viable solution for storing this clean energy. Lead-acid batteries are typically used, but are toxic and cannot endure continuous cycling, which degrades the performance of the battery significantly over time.
BIG momo play read it carefully